Athena Athena

X
[{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo initiates exploratory feasibility studies of amorphOX\u00ae with two leading biopharmaceutical and vaccine companies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Orexo"},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo Submits New Drug Application to FDA for OX124, A High-Dose Rescue Medication for Opioid Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Orexo"},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo Shares New Timeline for The High-Dose Rescue Medication for Opioid Overdose, OX124","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Orexo"},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo Submits New Drug Application to FDA for OX124, a High-dose Rescue Medication for Opioid Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Orexo"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            OX124 (naloxone), is based on Orexo´s world-class drug delivery platform amorphOX® and is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl.

            Lead Product(s): Naloxone Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: OX124

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 18, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            OX124 (naloxone), developed using amorphOXTM platform, is a powerful high-dose naloxone rescue medication, designed to reverse opioid overdoses, including those from highly potent synthetic opioids, such as fentanyl.

            Lead Product(s): Naloxone Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: OX124

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            OX124 (naloxone hydrochloride) is a competitive inhibitor of the µ-opioid receptor.7,12 Naloxone antagonizes the action of opioids, reversing their effects. It is being investigated as nasal delivery for opioid overuse.

            Lead Product(s): Naloxone Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: OX124

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            OX124 (naloxone), developed using amorphOXTM platform, is a powerful high-dose naloxone rescue medication, designed to reverse opioid overdoses, including those from highly potent synthetic opioids, such as fentanyl.

            Lead Product(s): Naloxone Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: OX124

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY